Institutional investors purchased a net $2.0 million shares of SGMO during the quarter ended December 2017 and now own 65.59% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
PEREGRINE CAPITAL MANAGEMENT LLC Bought 400.4 Thousand shares of Sangamo Therapeutics Inc